Dmitry Balyasny’s BridgeBio Pharma BBIO Stock Holding History

Dmitry Balyasny’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-91,200	Closed	-$6.98M	–	2895
2025 Q4	$6.98M	Sell	91,200 -12,300	-12%	-$807K	0.01%	1215
2025 Q3	$5.38M	Buy	103,500 +14,300	+16%	+$697K	0.01%	1344
2025 Q2	$3.85M	Buy	89,200 +69,800	+360%	+$2.54M	0.01%	1409
2025 Q1	$671K	Buy	+19,400	New	+$654K	﹤0.01%	2169
2024 Q4	–	Sell	-69,900	Closed	-$1.78M	–	2735
2024 Q3	$1.78M	Buy	+69,900	New	+$1.84M	﹤0.01%	1723
2022 Q4	–	Sell	-25,000	Closed	-$249K	–	2777
2022 Q3	$249K	Buy	+25,000	New	+$260K	﹤0.01%	2253
2022 Q1	–	Sell	-48,700	Closed	-$812K	–	2471
2021 Q4	$812K	Buy	+48,700	New	+$2.06M	﹤0.01%	1500
2021 Q1	–	Sell	-50,000	Closed	-$3.56M	–	1756
2020 Q4	$3.56M	Buy	+50,000	New	+$2.41M	0.02%	747

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Dmitry Balyasny's BBIO Position: Q2 2026 in Review

Dmitry Balyasny increased its BridgeBio Pharma (BBIO) stake by 251% in Q2 2026, buying an estimated $61.6M and bringing the position to 1,230,052 shares worth $91.6M. The position accounts for 0.11% of the portfolio, ranked #208.

Dmitry Balyasny first reported a position in BBIO in Q1 2022 and has held it in 10 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Dmitry Balyasny held 1,230,052 shares of BridgeBio Pharma worth $91.6M as of Q2 2026.
Dmitry Balyasny bought 879,956 BridgeBio Pharma shares in Q2 2026, an estimated $61.6M.
BridgeBio Pharma made up 0.11% of Dmitry Balyasny's portfolio in Q2 2026, its #208 holding.
Dmitry Balyasny first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 10 quarters since.
471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.